Federal Supply Schedule 36F79721D0239
Award Date
9/15/21
Last Date to Order
9/14/26
Federal Agency
Veterans Integrated Service Network 12
Awardee
Travere Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
Travere Therapeutics, Inc. holds a Blanket Purchase Agreement (BPA) with the Department of Veterans Affairs (VA) National Acquisition Center valued at $25,000,000. This BPA is specifically for the procurement of Travere's pharmaceutical products Thiola and Cholbam, which are used to treat rare kidney and liver conditions, respectively. Travere also holds a Federal Supply Schedule (FSS) contract with the VA for Pharmaceuticals and Drugs (FSS-61-IB), valued up to $14,970,593.10, which serves as...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Travere Therapeutics, Inc. for the procurement of cholbam and thiola from the Pharmaceuticals and Drugs Federal Supply Schedule. The single award BPA has a potential value of $25 million and a period of performance through September 14, 2021.
The BPA utilizes Travere Therapeutics' position on the GSA Pharmaceuticals and Drugs Schedule to establish fixed pricing, terms, and...
This federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Trevena, Inc. The contract, identified as 36F79721D0151, is under the Pharmaceuticals and Drugs (FSS-61-IB) master schedule and has a period of performance through May 14, 2026.
The contract aims to procure a variety of pharmaceutical and hematology-related products for the VA's healthcare system. As an unrestricted multiple-award contract, it provides a streamlined...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans.
In addition to the FSS...
Actelion Pharmaceuticals US, Inc., a large for-profit pharmaceutical manufacturer, holds multiple Indefinite Delivery Vehicles (IDVs) with the U.S. Department of Veterans Affairs (VA) to provide specialized drug therapies, primarily for the treatment of pulmonary arterial hypertension. These include a $219,108,390 Federal Supply Schedule (FSS-61-IB) contract and two Blanket Purchase Agreements (BPAs) valued at $118.5 million and $83.5 million. The IDVs allow federal agencies, such as the VA...
The Department of Veterans Affairs (VA) has awarded Chiesi USA Inc., a foreign-owned for-profit pharmaceutical company, an Indefinite Delivery/Indefinite Quantity (ID/IQ) Federal Supply Schedule (FSS) contract valued at up to $27.7 million for Pharmaceuticals and Drugs (FSS-61-IB). Under this contract, the VA has issued multiple firm fixed price delivery orders to Chiesi USA Inc. for the supply of deferiprone tablets in 1,000 mg doses to VA networks and facilities, including VISN 5, VISN 12,...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract and a single award Blanket Purchase Agreement (BPA) to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, to provide pharmaceuticals and drug products.
The FSS contract, valued up to $78 million through July 2025, and the BPA, valued up to $11.75 million from October 2021 to September 2025, allow the VA to procure pharmaceuticals such as TEGSEDI, used to treat...
The U.S. Department of Veterans Affairs (VA) has awarded a $198 million Federal Supply Schedule (FSS) contract and a $50 million Blanket Purchase Agreement (BPA) to United Therapeutics Corporation, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods. These Indefinite Delivery Vehicles (IDVs) allow the VA to efficiently procure United Therapeutics' specialized drug portfolio, including treatments for pulmonary arterial hypertension and certain types of...
The Department of Veterans Affairs Veterans Health Administration awarded a Federal Supply Schedule contract to Chemocentryx, Inc. for drugs, pharmaceuticals, and hematology related products with an estimated value of $225,000. No set-aside was used. The multiple award FSS has a period of performance through August 2027.
Additionally, the VA National Acquisition Center established a single-award Blanket Purchase Agreement with Chemocentryx valued at an estimated $12,000,000 for the drug...
The Department of Veterans Affairs (VA) awarded a single-award Blanket Purchase Agreement (BPA) to Recordati Rare Diseases Inc., a division of the Recordati Group, under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. The $3,156,115.00 BPA covers a period of performance from July 2021 to July 2025 and allows the VA to efficiently procure a range of Recordati's specialized orphan drugs, including Signifor, Carbaglu, Cystadane, Isturisa, and Cystadrops.
These medications are...